Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
A Phase 1 Non-Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety- and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Jen Rito
- Phone Number: (800) 466-6059
- Email: info@aligos.com
Study Locations
-
-
Florida
-
Orlando, Florida, United States, 32809
- Orlando Clinical Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and Female between 18 and 75 years old
- BMI 17.5 to 40.0 kg/m^2 and a total body weight >50 kg (110 lb)
- Female subjects must either be not of childbearing potential or if they are a woman of childbearing potential, they are only eligible if they and any non- sterile, male sexual partners agree to use highly effective contraceptive therapy
- Female subjects must have a negative serum pregnancy test at screening
Inclusion Criteria for Subjects with Normal Hepatic Function:
- Good general health as defined by no clinically relevant abnormalities identified by Medical History and a vital signs and 12-lead electrocardiogram (ECG) assessment
- Subjects must fit the demographic-matching criteria including body weight, age, and to the extent possible, gender
- Normal hepatic function with no known or suspected hepatic impairment
Inclusion Criteria for Subjects with Impaired Hepatic Function:
- Subject satisfies the criteria for Class B of the Child-Pugh classification (Child Pugh Scores 7-9 points) within 28 days of study drug administration
- A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination, liver biopsy, hepatic ultrasound, Fibroscan, computerized tomography scan, or magnetic resonance imaging (MRI)
- Stable hepatic impairment for at least 3 months prior to screening or second screening visit to demonstrate stability
- Stable concomitant medications for the management of an individual subject's medical history for at least 28 days prior to screening Subjects must have a 12-lead ECG and vital signs assessment that meet the protocol criteria
Exclusion Criteria for All Subjects:
- Subjects with any current or previous illness that, in the opinion of the Investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject or that could prevent, limit, or confound the protocol specified assessments or study results' interpretation
- Subjects with a past history of cardiac arrhythmias, risk factors for Torsade de Pointes syndrome (e.g., hypokalemia, family history of long QT Syndrome) or history or clinical evidence at screening of significant or unstable cardiac disease etc.
- Subjects with a history of clinically significant drug allergy
- Subjects with a recent (within 1 year of randomization) history or current evidence of drug abuse or recreational drug use
- Excessive use of alcohol defined as regular consumption of ≥14 units/ week for women and ≥21 units/week for men
- Unwilling to abstain from alcohol use for 48 hours prior to start of the study through end of study follow up
- Subjects with Hepatitis A, B, C, E or HIV-1/HIV-2 infection or acute infections such as SARS- CoV-2 infection. Subjects provided they met stable treatment criteria. Subjects with HIV infection may be eligible for moderate impairment cohort provided they met stable treatment criteria.
Exclusion Criteria for Subjects with Normal Hepatic Function:
- Estimated creatinine clearance <60 mL/min/1.73 m2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula] - Unless otherwise instructed by the Study Review Committee (SRC), CKD-EPI should not be corrected for subjects of African ancestry
- Bilirubin (total, direct) >1.2× upper limit of normal (ULN) (unless Gilbert's is suspected)
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level > 1.2×ULN
- Grade ≥1 Hemoglobin
Exclusion Criteria for Subjects with Impaired Hepatic Function:
- Subjects with advanced ascites (Grade 3)
- Subjects with refractory encephalopathy as judged by the investigator.
- Subjects with esophageal variceal bleeding within the past 6 months prior to screening.
- Subjects with Transjugular Intrahepatic Portosystemic Shunt (TIPS) placement.
- Estimated creatinine clearance <60 mL/min/1.73 m2 at screening, calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula] - Unless otherwise instructed by the SRC, CKD-EPI should not be corrected for subjects of African ancestry
- ALT or AST level ≥5×ULN
- Serum sodium ≤125 mmol/L
- Platelets <50×10^9/L
- Grade ≥2 Hemoglobin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Subjects with Hepatic Impairment
Subjects with hepatic impairment will receive single oral doses of 100 mg pevifoscorvir sodium.
Subjects will be followed up for 14 days after the administration of study drug.
|
Pevifoscorvir Sodium (ALG-000184) Single oral doses of 100 mg pevifoscorvir sodium
|
|
Experimental: Subjects without Hepatic impairment
Subjects without hepatic impairment will receive single oral doses of 100 mg pevifoscorvir sodium.
Subjects will be followed up for 14 days after the administration of study drug.
|
Pevifoscorvir Sodium (ALG-000184) Single oral doses of 100 mg pevifoscorvir sodium
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area under the concentration time curve [AUC]
Time Frame: Up to 4 days
|
PK parameters of total ALG-001075 and the major metabolite ALG-000302 in plasma
|
Up to 4 days
|
|
Time to maximum plasma concentration [Tmax]
Time Frame: Update to 4 Days
|
PK parameters of total ALG-001075 and the major metabolite ALG-000302 in plasma
|
Update to 4 Days
|
|
Maximum plasma concentration [Cmax]
Time Frame: Update to 4 days
|
PK parameters of total ALG-001075 and the major metabolite ALG-000302 in plasma
|
Update to 4 days
|
|
Minimum plasma concentration [Cmin]
Time Frame: Up to 4 days
|
PK parameters of total ALG-001075 and the major metabolite ALG-000302 in plasma
|
Up to 4 days
|
|
C0 (predose)
Time Frame: Up to 4 days
|
PK parameters of total ALG-001075 and the major metabolite ALG-000302 in plasma
|
Up to 4 days
|
|
Half-life [t1/2]
Time Frame: Up to 4 Days
|
PK parameters of total ALG-001075 and the major metabolite ALG-000302 in plasma
|
Up to 4 Days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: Up to 15 days
|
The number and severity of treatment emergent adverse events as assessed by DAIDS v2.1
|
Up to 15 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- ALG-000184-207
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.